Nilotinib Less Effective Than Imatinib to Treat First-Line Gastrointestinal Tumors

Share this content:
Nilotinib cannot be recommended for broad use as the first-line treatment of patients with GISTs.
Nilotinib cannot be recommended for broad use as the first-line treatment of patients with GISTs.

Nilotinib cannot be recommended for broad use as the first-line treatment of patients with gastrointestinal stromal tumors (GISTs), a recent study published in the journal The Lancet Oncology has concluded.

Because nilotinib has activity against platelet-derived growth factor receptors (PDGFRs), and mutations in PDGFRα are key drivers in most GISTS, researchers sought to compare the efficacy and safety of nilotinib versus imatinib as first-line therapy for patients with advanced GISTs.

For the open-label, multicenter, phase III trial, researchers enrolled 647 patients and randomly assigned them 1:1 to receive oral imatinib 400mg once daily or nilotinib 400mg twice daily.

Results showed that 2-year progression free survival was 59.2% (95% CI: 50.9-66.5) in the imatinib group compared with 51.6% (95% CI: 43.0-59.5) in the nilotinib group (HR = 1.47; 95% CI: 1.10-1.95).

In regard to safety, the most common grade 3-4 adverse events in the imatinib group were hypophosphatemia, anemia, abdominal pain, and elevated lipase level.

RELATED: Potential Therapy for Rare, Drug-resistant GISTs

In the nilotinib group, the most common grade 3-4 adverse events were anemia, elevated lipase level, increased alanine aminotransferase concentration, and abdominal pain. Serious abdominal pain was experienced by 4% of patients in each group.

Although the findings show that nilotinib is less effective than imatinib for first-line treatment of patients with GIST, the authors conclude that future studies may identify certain patients who would benefit from nilotinib treatment.

Reference

  1. Blay J-Y, Shen L, Kang Y-K, et al. Nilotinib versus imatinib as first-line therapy for patients with unresectable or metastatic gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 trial. Lancet Oncol. 2015. [Epub ahead of print]. doi: 10.1016/S1470-2045(15)70105-1.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters